3-Month Formulation of Goserelin Acetate (‘Zoladex’ 10.8-mg Depot) in Advanced Prostate Cancer: Results from an Italian, Open, Multicenter Trial
| Autor: | Ss Maymone, C Boccafoschi, M Frongia, A Zanollo, Carlo Magno, Dario Fontana, G Montagna, U. Jacobellis, Sc Cunico, M Turriziani, M. Mari, A Martinelli |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class Injections Subcutaneous Urology medicine.medical_treatment Antiandrogen Prostate cancer Multicenter trial Humans Medicine Testosterone Aged Aged 80 and over Prostatectomy business.industry Goserelin Acetate Goserelin Prostatic Neoplasms Middle Aged Prostate-Specific Antigen medicine.disease Surgery Prostate-specific antigen Tolerability Delayed-Action Preparations business medicine.drug |
| Zdroj: | Urologia Internationalis. 70:316-320 |
| ISSN: | 1423-0399 0042-1138 |
| DOI: | 10.1159/000070142 |
| Popis: | Objectives: To determine the endocrine effects, efficacy and tolerability of the 3-month formulation of goserelin acetate (‘Zoladex’ 10.8-mg depot; ‘Zoladex’ is a trade mark of the AstraZeneca group of companies) in the treatment of patients with advanced prostate cancer. Methods: Between February 1996 and October 1997, this open, multicentre study enrolled 120 patients with locally advanced (T3/4) or metastatic (N+ or M1) disease, or an increase in prostate-specific antigen (PSA) level after radical prostatectomy. Patients received goserelin acetate 10.8-mg depot every 12 weeks until clinical progression or interruption for adverse events or other reasons. Results: The mean testosterone concentrations were suppressed to the castration range (≤2 nmol/l) after 4 weeks of treatment and remained suppressed throughout the study. In total, 99/115 (86%) patients had a serum PSA response, and the mean PSA value decreased significantly during treatment (p = 0.006). The mean PSA level at baseline was significantly lower in patients without disease progression compared to those who experienced disease progression (p = 0.0002). Goserelin acetate 10.8-mg depot was well tolerated and there were no injection site reactions. Conclusions: The goserelin acetate 10.8-mg depot is well tolerated with no injection site reactions. It produces PSA responses and provides reliable suppression of serum testosterone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|